A number of research firms have changed their ratings and price targets for Catalent (NYSE: CTLT):

  • 11/16/2018 – Catalent was given a new $45.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 11/15/2018 – Catalent is now covered by analysts at Robert W. Baird. They set an “outperform” rating on the stock.
  • 11/12/2018 – Catalent was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 11/12/2018 – Catalent was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 11/7/2018 – Catalent was upgraded by analysts at First Analysis from a “neutral” rating to an “outperform” rating. They now have a $43.00 price target on the stock, down previously from $47.00.
  • 11/7/2018 – Catalent was downgraded by analysts at TheStreet from a “b-” rating to a “c+” rating.
  • 11/7/2018 – Catalent was given a new $44.00 price target on by analysts at Royal Bank of Canada. They now have a “buy” rating on the stock.
  • 11/6/2018 – Catalent was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 10/30/2018 – Catalent was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
  • 10/9/2018 – Catalent is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $48.00 price target on the stock.
  • 10/1/2018 – Catalent was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

Shares of NYSE CTLT opened at $37.72 on Tuesday. Catalent Inc has a fifty-two week low of $34.24 and a fifty-two week high of $47.87. The company has a current ratio of 2.05, a quick ratio of 1.61 and a debt-to-equity ratio of 1.44. The stock has a market cap of $5.73 billion, a P/E ratio of 23.72, a P/E/G ratio of 2.46 and a beta of 1.45.

Catalent (NYSE:CTLT) last issued its quarterly earnings data on Tuesday, November 6th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Catalent had a net margin of 2.65% and a return on equity of 19.13%. The business had revenue of $551.80 million for the quarter, compared to analysts’ expectations of $582.44 million. During the same period in the previous year, the business earned $0.21 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. As a group, analysts predict that Catalent Inc will post 1.64 earnings per share for the current fiscal year.

In other Catalent news, insider Barry Littlejohns sold 47,265 shares of the business’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $41.64, for a total value of $1,968,114.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John J. Greisch purchased 13,000 shares of the company’s stock in a transaction on Thursday, November 8th. The stock was acquired at an average price of $37.61 per share, for a total transaction of $488,930.00. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 184,335 shares of company stock worth $8,161,727. 1.40% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Nelson Van Denburg & Campbell Wealth Management Group LLC purchased a new position in Catalent during the 2nd quarter valued at about $145,000. Moneta Group Investment Advisors LLC grew its stake in Catalent by 105.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 3,515 shares of the company’s stock valued at $147,000 after acquiring an additional 1,800 shares in the last quarter. CIBC Asset Management Inc purchased a new position in Catalent during the 3rd quarter valued at about $217,000. Hartford Investment Management Co. purchased a new position in Catalent during the 2nd quarter valued at about $220,000. Finally, Rehmann Capital Advisory Group grew its stake in Catalent by 1,895.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 5,309 shares of the company’s stock valued at $222,000 after acquiring an additional 5,043 shares in the last quarter. Hedge funds and other institutional investors own 92.24% of the company’s stock.

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Story: What are the most popular ETFs

Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.